11 research outputs found
Haematological and Biochemical Characterization of Bubaline Trypanosomosis in Mumbai Region of India
The present study was based on observations on 17 cases of Trypanosoma evansi infection in buffaloes diagnosed by blood smear examination. The degree of parasitaemia revealed heavy (64.70%), moderate (23.52%) and mild (11.76%) infections in buffaloes.Haematological analysis revealed subnormal erythrocytic count and haemoglobin in 70.58% buffaloes. Leukocytosis was evident in 70.58% buffaloes with neutrophilia relatively associated with lymphocytopenia.Blood glucose level of 15 hypoglycaemic buffaloes ranged between 27 to 49.05 gm/dl with an average of 39.35 gm/dl. The comparative analysis of the degree of hypoglycaemia with parasitaemia revealed positive correlation between two parameters. Biochemical analysis of sera and blood samples showed increase level of BUN and serum creatinine in 17.64% buffaloes
<i>In Vivo</i> Efficacy of a Synthetic Coumarin Derivative in a Murine Model of Aspergillosis
<div><p>Despite advances in therapeutic modalities, aspergillosis remains a leading cause of mortality. This has necessitated the identification of effective and safe antifungal molecules. In the present study, <i>in vivo</i> safety and antifungal efficacy of a coumarin derivative, <i>N</i>, <i>N, N</i>-Triethyl-11-(4-methyl-2-oxo-2<i>H</i>-benzopyran-7-yloxy)-11-oxoundecan-1-aminium bromide (SCD-1), was investigated. The maximum tolerable dose of compound was determined according to OECD 423 guidelines. The compound could be assigned to category IV of the Globally Harmonized System and its LD<sub>50</sub> cut-off was found to be 2000 mg/kg body weight. The survival increased in <i>Aspergillus fumigatus-</i>infected mice treated with a dose of 200 mg/kg, orally or 100 mg/kg body weight, intraperitoneally, of SCD-1 in comparison to infected-untreated animals. The SCD-1 treatment resulted in significant reduction in colony counts in vital organs of the animals. Its protective effect was also observed on day 14 as there was marked reduction in fungal colonies. The treatment with SCD-1 also reduced the levels of serum biochemical parameters with respect to infected-untreated animals. It could be concluded that SCD-1 is a quite safe antifungal compound, which conferred dose dependent protection against experimental aspergillosis. Therefore, SCD-1 holds potential for developing new formulations for aspergillosis.</p></div
Fungal burden in different organs of experimental animals.
<p>The number of CFUs (Mean ± SE) were determined on 7<sup>th</sup> (A) and 14<sup>th</sup> (B) day of infection. Asterisks indicate statistically significant differences. *<i>p</i><0.05, **<i>p</i><0.001.</p
Survival rate in experimental mice.
<p>The animals were challenged intranasally with conidia of <i>A. fumigatus</i> and treated with different doses of SCD-1, daily, upto 14 days.</p
Treatment of infected mice with different doses of SCD-1.
<p>Treatment of infected mice with different doses of SCD-1.</p
Body weights of experimental mice.
<p>The daily weight (Mean ± SE) of animals belonging to different groups was recorded daily over a period of 14 days.</p